PH12021550033A1 - Tumor reduction formulations and methods of use thereof - Google Patents
Tumor reduction formulations and methods of use thereofInfo
- Publication number
- PH12021550033A1 PH12021550033A1 PH12021550033A PH12021550033A PH12021550033A1 PH 12021550033 A1 PH12021550033 A1 PH 12021550033A1 PH 12021550033 A PH12021550033 A PH 12021550033A PH 12021550033 A PH12021550033 A PH 12021550033A PH 12021550033 A1 PH12021550033 A1 PH 12021550033A1
- Authority
- PH
- Philippines
- Prior art keywords
- methods
- tumor reduction
- formulations
- reduction formulations
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to tumor reducing compositions and methods thereof. Specifically, the invention relates to compositions comprising a combination of a sclerosing agent and a penetrating agent.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862695613P | 2018-07-09 | 2018-07-09 | |
PCT/US2019/040264 WO2020023191A1 (en) | 2018-07-09 | 2019-07-02 | Tumor reduction formulations and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PH12021550033A1 true PH12021550033A1 (en) | 2021-09-20 |
Family
ID=75267393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH12021550033A PH12021550033A1 (en) | 2018-07-09 | 2021-01-06 | Tumor reduction formulations and methods of use thereof |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3820482A4 (en) |
JP (1) | JP2021530482A (en) |
KR (1) | KR20220098082A (en) |
CN (1) | CN112584841A (en) |
AU (1) | AU2019309757A1 (en) |
BR (1) | BR112021000279A8 (en) |
CA (1) | CA3105717A1 (en) |
EA (1) | EA202190201A1 (en) |
IL (1) | IL280000A (en) |
PH (1) | PH12021550033A1 (en) |
WO (1) | WO2020023191A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA202193111A1 (en) | 2019-05-14 | 2022-02-10 | Тайм, Инк. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
AU2020401131A1 (en) * | 2019-12-09 | 2022-07-14 | Tyme, Inc. | Pharmaceutical compositions and methods |
US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050202094A1 (en) * | 2004-01-29 | 2005-09-15 | Werling Jane O. | Nanosuspensions of anti-retroviral agents for increased central nervous system delivery |
WO2006099685A1 (en) * | 2005-03-24 | 2006-09-28 | Medical Therapies Limited | Method for the prophylaxis or treatment of carcinomas |
CN101023940A (en) * | 2006-02-20 | 2007-08-29 | 郝守祝 | Medicine composition of Taxane compounds, preparing method and use |
AU2015287749B2 (en) * | 2014-07-11 | 2021-03-11 | The Regents Of The University Of California | Tumor selective macropinocytosis-dependent rapidly internalizing antibodies |
US9687528B2 (en) * | 2014-12-23 | 2017-06-27 | Steven Hoffman | Transdermal formulations |
US20190091252A1 (en) * | 2016-03-15 | 2019-03-28 | Tyme, Inc. | Pharmaceutical compositions for the treatment of cancer |
-
2019
- 2019-07-02 CN CN201980054337.1A patent/CN112584841A/en active Pending
- 2019-07-02 JP JP2021500520A patent/JP2021530482A/en not_active Withdrawn
- 2019-07-02 CA CA3105717A patent/CA3105717A1/en active Pending
- 2019-07-02 EA EA202190201A patent/EA202190201A1/en unknown
- 2019-07-02 WO PCT/US2019/040264 patent/WO2020023191A1/en unknown
- 2019-07-02 EP EP19841949.1A patent/EP3820482A4/en not_active Withdrawn
- 2019-07-02 KR KR1020217003523A patent/KR20220098082A/en active Search and Examination
- 2019-07-02 BR BR112021000279A patent/BR112021000279A8/en not_active Application Discontinuation
- 2019-07-02 AU AU2019309757A patent/AU2019309757A1/en not_active Abandoned
-
2021
- 2021-01-06 PH PH12021550033A patent/PH12021550033A1/en unknown
- 2021-01-07 IL IL280000A patent/IL280000A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220098082A (en) | 2022-07-11 |
AU2019309757A1 (en) | 2021-03-04 |
CA3105717A1 (en) | 2020-01-30 |
WO2020023191A1 (en) | 2020-01-30 |
CN112584841A (en) | 2021-03-30 |
EA202190201A1 (en) | 2021-04-09 |
BR112021000279A8 (en) | 2021-04-20 |
IL280000A (en) | 2021-03-01 |
CN112584841A8 (en) | 2021-06-18 |
EP3820482A1 (en) | 2021-05-19 |
EP3820482A4 (en) | 2022-03-23 |
JP2021530482A (en) | 2021-11-11 |
BR112021000279A2 (en) | 2021-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023010042A (en) | Modulatory polynucleotides. | |
MX2021006531A (en) | Rna containing composition for treatment of tumor diseases. | |
MX2020007799A (en) | Gcn2 inhibitors and uses thereof. | |
PH12021550033A1 (en) | Tumor reduction formulations and methods of use thereof | |
MX2020007797A (en) | Gcn2 inhibitors and uses thereof. | |
IL278829A (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof | |
MX2017004808A (en) | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis. | |
MX2017011521A (en) | Topical compositions comprising a corticosteroid. | |
MX2020006596A (en) | Hydroxyisoxazolines and derivatives thereof. | |
MX2017008390A (en) | Alkoxysilane-functionalized and allophanate-functionalized urethanes. | |
TW201613578A (en) | Pharmaceutical combinations | |
MX2019010984A (en) | Synthekine compositions and methods of use. | |
WO2019043176A3 (en) | Hdac inhibitor in combination with antimetabolite agent for cancer therapy | |
IL272834A (en) | Amantadine compositions, preparations thereof, and methods of use | |
EP3793563A4 (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
ZA202000354B (en) | Novel braf inhibitors and use thereof for treatment of cutaneous reactions | |
PH12016501838A1 (en) | Compounds and their methods of use | |
MX2021000314A (en) | Tumor reduction formulations and methods of use thereof. | |
MX2021006977A (en) | Anellosomes and methods of use. | |
SG11202011041YA (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
MX2020011027A (en) | Trivalent trispecific antibody constructs. | |
EP3615020A4 (en) | Methods, agents, and compositions for the treatment of acute myeloid leukemia | |
EP3600277A4 (en) | Compositions for the treatment of drug-resistant tumors and methods of use thereof | |
MX2018014790A (en) | Combination formulation of three antiviral compounds. | |
GB201915828D0 (en) | Compounds, compositions and therapeutic uses thereof |